SCA
DMAC icon

Sandy Cove Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Sandy Cove Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,200
Closed -$3K – 151
2022
Q1 		$3K Hold
1,200
– – ﹤0.01% 372
2021
Q4 		$4K Buy
+1,200
New +$4.71K ﹤0.01% 331

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sandy Cove Advisors's DMAC Position: Q2 2022 in Review

Sandy Cove Advisors sold out of DiaMedica Therapeutics (DMAC) in Q2 2022, closing a stake of 1,200 shares — an estimated $3K sold.

Sandy Cove Advisors first reported a position in DMAC in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q4 2021. 28 funds tracked by Wall St. Rank hold DMAC as of Q2 2022.

  • Sandy Cove Advisors reported no remaining DiaMedica Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sandy Cove Advisors sold 1,200 DiaMedica Therapeutics shares in Q2 2022, an estimated $3K.
  • Sandy Cove Advisors first reported a position in DiaMedica Therapeutics in Q4 2021 and held it in 2 quarters.
  • Sandy Cove Advisors's DiaMedica Therapeutics position peaked at $4K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.